Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial — Christopher J. Sweeney (2021) | RDL Network
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Johann S. de Bono, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Josep Garcia, Małgorzata Nowicka, Matthew Wongchenko, Zhen Shi
Zhen Shi, Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Marie-Laurence Harle-Yge, Małgorzata Nowicka, Matthew Wongchenko, Johann S. de Bono
Nobuaki Matsubara, Johann S. de Bono, Christopher Sweeney, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Geng Chen, Adam Harris, Fanny Schenkel, Rucha Sane, Healther Hinton, Sergio Bracarda, Cora N. Sternberg
Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, B. Yа. Alekseev, Rustem Gafanov, Francis Parnis, Gary L. Buchschacher, Luis Corrales, Michael Borre, Gustavo Vasconcelos Alves, Josep Garcia, M-L. Harle-Yge, G. Chen, Matthew Wongchenko, Christopher J. Sweeney, Johann S. de Bono, Sergio Bracarda, Cora N. Sternberg, K.N. Chi, David Olmos
Cora N. Sternberg, Sergio Bracarda, Johann S. de Bono, Christopher J. Sweeney, K.N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Josep Garcia, Fanny Schenkel, G. Chen, Adam Harris, Heather Hinton, Nobuaki Matsubara
Discussion(0)
No comments yet. Be the first to comment.